(NASDAQ: ARVN) Arvinas's forecast annual revenue growth rate of -6.14% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.63%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.75%.
Arvinas's revenue in 2026 is $89,400,000.On average, 17 Wall Street analysts forecast ARVN's revenue for 2026 to be $7,701,250,193, with the lowest ARVN revenue forecast at $3,334,455,513, and the highest ARVN revenue forecast at $13,077,801,623. On average, 17 Wall Street analysts forecast ARVN's revenue for 2027 to be $4,398,216,504, with the lowest ARVN revenue forecast at $1,568,574,845, and the highest ARVN revenue forecast at $8,516,152,924.
In 2028, ARVN is forecast to generate $5,730,579,243 in revenue, with the lowest revenue forecast at $2,141,974,731 and the highest revenue forecast at $13,366,856,590.